These guidelines establish evidence-based recommendations for the clinical use and interpretation of cardiac troponin and natriuretic peptides in conditions outside of acute coronary syndromes and heart failure, such as chronic renal failure.
Answers are grounded in this paper and cite their sources.
Adopt dynamic troponin criteria for AMI diagnosis in ESRD; extends evidence-based biomarker guidance to chronic kidney disease.
No abstract was published with this document — society guidelines, consensus pathways, and scientific statements are typically released without one. See the Key Points and the linked PDF for the full content.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: